clozapine

Therapeutic Classification: antipsychotics

BEERS REMS

Schizophrenia unresponsive to or intolerant of standard therapy with other antipsychotics (treatment refractory).
To reduce recurrent suicidal behavior in schizophrenic patients.

Binds to dopamine receptors in the CNS.
Also has anticholinergic and alpha-adrenergic blocking activity.
Produces fewer extrapyramidal reactions and less tardive dyskinesia than standard antipsychotics but carries high risk of hematologic abnormalities.

Therapeutic effects:

Diminished schizophrenic behavior.
Diminished suicidal behavior.

Absorption: Well absorbed after oral administration.

Distribution: Rapid and extensive distribution; crosses blood-brain barrier.

Protein Binding: 95%.

Metabolism/Excretion: Mostly metabolized through the liver by the CYP1A2, CYP2D6, and CYP3A4 isoenzymes; (the CYP2D6 enzyme system exhibits genetic polymorphism; ∼7% of population may be poor metabolizers and may have significantly ↑ clozapine concentrations and an ↑ risk of adverse effects).

Half-Life: 8–12 hr.

(antipsychotic effect)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	wk	4–12 hr

Contraindicated in:

Hypersensitivity;
Bone marrow depression;
Severe CNS depression/coma;
Uncontrolled epilepsy;
Clozapine-induced agranulocytosis or severe granulocytopenia;
Lactation: Lactation.

Use Cautiously in:

Long QT syndrome;
Risk factors for QT interval prolongation or ventricular arrhythmias (i.e., recent myocardial infarction, heart failure, arrhythmias);
Concurrent use of CYP1A2, CYP2D6, or CYP3A4 inhibitors or QT-interval prolonging drugs;
Hypokalemia or hypomagnesemia;
Presence/history of constipation, urinary retention, or prostatic hypertrophy;
Angle-closure glaucoma;
Malnourished or dehydrated patients and patients with cardiovascular, cerebrovascular, hepatic, or renal disease, or patients on antihypertensives (use lower initial dose, titrate more slowly);
Risk factors for stroke (↑ risk of stroke in patients with dementia);
Diabetes;
Seizure disorder;
Patients at risk for falls;
OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk; neonates at risk for extrapyramidal symptoms and withdrawal after delivery when exposed during the 3rd trimester;
Pedi: Children 16 yr (safety and effectiveness not established);
Geri: Appears on Beers list. risk of stroke, cognitive decline, and mortality in older adults with dementia. Avoid use in older adults, except for schizophrenia, bipolar disorder, or psychosis in Parkinson's disease.

CV: hypotension, tachycardia, bradycardia, CARDIAC ARREST, DEEP VEIN THROMBOSIS, HF, hypertension, MITRAL VALVE INCOMPETENCE, MYOCARDITIS, QT interval prolongation, syncope, TORSADES DE POINTES, VENTRICULAR ARRHYTHMIAS

Derm: rash, sweating

EENT: visual disturbances

Endo: hyperglycemia

GI: constipation, ↑salivation, abdominal discomfort, dry mouth, GI ISCHEMIA/INFARCTION/NECROSIS, GI OBSTRUCTION, GI PERFORATION, HEPATOTOXICITY, nausea, ulceration, vomiting

GU: nocturnal enuresis

Hemat: AGRANULOCYTOSIS, LEUKOPENIA

Metab: hyperlipidemia, weight gain

Neuro: dizziness, sedation, extrapyramidal reactions, NEUROLEPTIC MALIGNANT SYNDROME, SEIZURES

Resp: PULMONARY EMBOLISM

Misc: fever

Drug-drug:

↑anticholinergic effects with other anticholinergic drugs, including antihistamines, quinidine, disopyramide, and antidepressants; avoid concurrent use.
Concurrent use with strong CYP1A2 inhibitors, including fluvoxamine or ciprofloxacin may ↑ levels; ↓ clozapine dose to ⅓ of the original dose during concurrent use.
Concurrent use with moderate or weak CYP1A2 inhibitors, including oral contraceptives or caffeine may ↑ levels; consider ↓ clozapine dose
Concurrent use with CYP2D6 inhibitors or CYP3A4 inhibitors, including cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline may ↑ levels; consider ↓ clozapine dose
Concurrent use with CYP1A2 inducers or CYP3A4 inducers, including nicotine, carbamazepine, phenytoin, or rifampin may ↓ levels; concurrent use with strong CYP3A4 inducers not recommended
↑CNS depression with alcohol, antidepressants, antihistamines, opioid analgesics, or sedative/hypnotics.
↑hypotension with nitrates, acute ingestion of alcohol, or antihypertensives.
↑risk of bone marrow suppression with antineoplastics or radiation therapy.
Use with lithium↑ risk of adverse CNS reactions, including seizures.
↑risk of QT interval prolongation with other QT interval prolonging agents.

Drug-Natural Products:

Caffeine-containing herbs (cola nut, tea, coffee) may ↑ levels and side effects.
St. John’s wort may ↓ blood levels and efficacy.

PO (Adults ): 12.5 mg 1–2 times daily initially; ↑ by 25–50 mg/day over a period of 2 wk up to target dose of 300–450 mg/day. May then be ↑ by up to 100 mg/day once or twice weekly (not to exceed 900 mg/day). Treatment should be continued for at least 2 yr in patients with suicidal behavior.

(Generic available)

Tablets (Clozaril): 25 mg; 50 mg; 100 mg; 200 mg
Orally disintegrating tabletsmint: 12.5 mg; 25 mg; 100 mg; 150 mg; 200 mg
Oral suspension (Versacloz): 50 mg/mL

Monitor patient’s mental status (orientation, mood, behavior) before and periodically during therapy. Titrate slowly and monitor closely; may cause orthostatic hypotension, bradycardia, syncope, and cardiac arrest.
Monitor BP (sitting, standing, lying) and pulse rate before and frequently during initial dose titration.
Assess weight and BMI initially and periodically during therapy. Refer as appropriate for nutritional/weight management and medical management.
Observe patient carefully when administering medication to ensure that medication is actually taken and not hoarded or cheeked.
Monitor for signs of myocarditis (unexplained fatigue, dyspnea, tachypnea, fever, chest pain, palpitations, other signs and symptoms of heart failure, ECG changes, such as ST-T wave abnormalities, arrhythmias, or tachycardia during first mo of therapy). If these occur, clozapine should be discontinued and not restarted.
Monitor patient for onset of akathisia (restlessness or desire to keep moving) and extrapyramidal side effects (parkinsonian: difficulty speaking or swallowing, loss of balance control, pill-rolling motion of hands, mask-like face, shuffling gait, rigidity, tremors and dystonic muscle spasms, twisting motions, twitching, inability to move eyes, weakness of arms or legs) every 2 mo during therapy and 8–12 wk after therapy has been discontinued. Notify health care professional if these symptoms occur; reduction in dose or discontinuation of medication may be necessary. Trihexyphenidyl or benzotropine may be used to control these symptoms.
Monitor for possible tardive dyskinesia (uncontrolled rhythmic movement of mouth, face, and extremities; lip smacking or puckering; puffing of cheeks; uncontrolled chewing; rapid or worm-like movements of tongue). Report these symptoms immediately; may be irreversible.
Monitor frequency and consistency of bowel movements and assess for symptoms of hypomotility (nausea, vomiting, abdominal distension, abdominal pain). Symptoms range from constipation to paralytic ileus; risk increased with use of other anticholinergic medications. Increasing bulk and fluids in the diet, and laxatives may help to minimize constipation. Prophylactic laxatives may be used for high-risk patients.
Clozapine lowers the seizure threshold. Institute seizure precautions for patients with history of seizure disorder.
Transient fevers may occur, especially during first 3 wk of therapy. Fever is usually self-limiting but may require discontinuation of medication. Also, monitor for development of neuroleptic malignant syndrome (fever, respiratory distress, tachycardia, seizures, diaphoresis, hypertension or hypotension, pallor, tiredness). Notify health care professional immediately if these symptoms occur.
Assess respiratory status during therapy. If deep-vein thrombosis, acute dyspnea, chest pain, or other respiratory signs and symptoms occur, consider pulmonary embolism.
Assess for falls risk. Drowsiness, orthostatic hypotension, and motor and sensory instability increase risk. Institute prevention if indicated.
Monitor for signs and symptoms of hepatotoxicity (fatigue, malaise, anorexia, nausea, jaundice, hyperbilirubinemia, coagulopathy, hepatic encephalopathy). May require permanent discontinuation if combined with elevated transaminases.

Lab Test Considerations:

Monitor WBC, absolute neutrophil count (ANC), and differential count before starting therapy. ANC must be ≥1500/mm³ for the general population and ≥1000/mm³ for patients with documented Benign Ethnic Neutropenia (BEN) for patient to begin therapy. Monitor ANC weekly for the first 6 mo, then biweekly for the second 6 mo, then, if maintained within acceptable parameters, monthly after 12 mo. If mild neutropenia (ANC 1000–1499/mm³) occurs, continue therapy and monitor ANC 3 times/wk until ANC ≥1500/mm³. Once ANC ≥1500/mm³, return to patient's last ANC monitoring interval. If moderate neutropenia (ANC 500–999/mm³) occurs, recommend hematology consultation. Interrupt therapy for suspected clozapine-induced neutropenia. Resume therapy once ANC ≥1000/mm³. Monitor ANC daily until ANC ≥1000/mm³ then 3 times/wk until ANC ≥1500/mm³. Once ANC ≥1500/mm³, check ANC weekly for 4 wk, then return to patient's last ANC monitoring interval. If severe neutropenia (<500/mm³) occurs, recommend hematology consultation. Interrupt therapy for suspected clozapine-induced neutropenia. Do not rechallenge unless benefit outweighs risk. Monitor ANC daily until ANC ≥1000/mm³, then 3 times/wk until ANC ≥1500/mm³. If patient rechallenged, resume therapy as a new patient using normal monitoring once ANC ≥1500/mm³. For patients with Benign Ethnic Neutropenia (BEN), obtain at least 2 baseline ANC levels before starting therapy. Monitor ANC weekly for the first 6 mo, then biweekly for the second 6 mo, then, if maintained within acceptable parameters, monthly after 12 mo. If neutropenia (ANC 500–999/mm³) occurs, recommend hematology consultation and continue therapy. Monitor ANC 3 times/wk until ANC ≥1000/mm³ or at patient's known baseline. Once ANC ≥1000/mm³, check ANC weekly for 4 wk, then return to patient's last ANC monitoring interval. If severe neutropenia (<500/mm³) occurs, recommend hematology consultation. Interrupt therapy for suspected clozapine-induced neutropenia. Do not rechallenge. Monitor ANC daily until ANC ≥500/mm³, then 3 times/wk until ANC ≥patient's baseline. If patient rechallenged, resume therapy as a new patient using normal monitoring once ANC ≥1000/mm³ or at patient's baseline.
- Assess fasting blood glucose and cholesterol levels initially and throughout therapy.
- Monitor liver function tests periodically during therapy or if clinical signs of hepatotoxicity occur.

Toxicity and Overdose:

Overdose is treated with activated charcoal and supportive therapy. Monitor patient for several days because of risk of delayed effects.
- Avoid use of epinephrine and its derivatives when treating hypotension, and avoid quinidine and procainamide when treating arrhythmias.

Do not confuse clozapine with clonazepam or clonidine. Do not confuse Clozaril with Colazal.
Because of the risk of severe neutropenia, clozapine is only available through a restricted program called Clozapine REMS Program. Health care professionals must be trained and certified to prescribe clozapine. Patients must be enrolled in the program and comply with ANC testing and monitoring requirements. Pharmacies dispensing clozapine must be trained and certified with program and must dispense only to patients eligible to receive clozapine.
Discontinue therapy over 1–2 wk. For abrupt discontinuation unrelated to neutropenia, continue ANC monitoring for general population patients until ANC ≥1500/mm³ and for BEN patients until their ANC is ≥1000/mm³ or above their baseline. Monitor for recurrence of psychotic symptoms and symptoms related to cholinergic rebound (profuse sweating, headache, nausea, vomiting, diarrhea).
When restarting clozapine in patients after even a brief interruption in therapy, dose must be reduced to minimize risk of hypotension, bradycardia, and syncope. If one day’s dosing has been missed, resume treatment at 40% to 50% of the established dose. If two days dosing has been missed, resume dose at approximately 25% of established dosage. For longer interruptions, re-initiate with a dose of 12.5 mg once daily or twice daily. If these doses are well tolerated, the dose may be increased to previous dose more quickly than recommended for initial treatment.
PO: Administer capsules with food or milk to decrease gastric irritation.
- Leave oral disintegrating tablet in blister until time of use. Do not push tablet through foil. Just before use, peel foil and gently remove disintegrating tablet. Immediately place tablet in mouth and allow to disintegrate and swallow with saliva. If ½ tablet dose used, destroy other half of tablet.
- Oral solution may be taken without regard to food. Shake bottle for suspension for 10 sec prior to withdrawing. Use oral syringes and oral adaptor provided for accurate dosing. Do not store dose in syringe; wash between doses.

Instruct patient to take medication as directed. If clozapine is stopped for >2 days, do not restart medication, notify health care professional for new dosing instructions. Patients on long-term therapy may need to discontinue gradually over 1–2 wk.
Explain purpose and procedures of Clozapine REMS Program to patient.
Inform patient of possibility of extrapyramidal symptoms. Instruct patient to report these symptoms immediately.
Inform patient that cigarette smoking can decrease clozapine levels. Risk for relapse increases if patient begins or increases smoking.
Advise patient to change positions slowly to minimize orthostatic hypotension. Protect from falls.
May cause seizures and drowsiness. Caution patient to avoid driving or other activities requiring alertness while taking clozapine.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking any other medications. Caution patient to avoid concurrent use of alcohol and other CNS depressants.
Instruct patient to use frequent mouth rinses, good oral hygiene, and sugarless gum or candy to minimize dry mouth.
Advise patient to notify health care professional of medication regimen before treatment or surgery.
Instruct patient to notify health care professional promptly if unexplained fatigue, dyspnea, tachypnea, chest pain, palpitations, sore throat, fever, lethargy, weakness, malaise, constipation, or flu-like symptoms occur.
Rep: May cause fetal harm. Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breastfeeding. Consider early screening for gestational diabetes if used during pregnancy. Neonates exposed to antipsychotic drugs during third trimester are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Monitor neonates for symptoms of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, excessive sedation, and feeding difficulties. Monitor infants exposed to clozapine through breast milk for excessive sedation.
Advise patient of need for continued medical follow-up for psychotherapy, eye exams, and laboratory tests.

Decreased positive symptoms (delusions, hallucinations) of schizophrenia.
Decrease in negative symptoms (social withdrawal; flat, blunt affect) of schizophrenia.

Clozaril, ~~FazaClo,~~ Versacloz

NDC Code

0093- Teva Pharmaceuticals USA Inc
- 0093-3010- Clozapine
  - 0093-3010-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (0093-3010-01)

0093- Teva Pharmaceuticals USA Inc
- 0093-3086- Clozapine
  - 0093-3086-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (0093-3086-01)

0093- Teva Pharmaceuticals USA Inc
- 0093-3086- Clozapine
  - 0093-3086-19- 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-3086-19)

0093- Teva Pharmaceuticals USA Inc
- 0093-3086- Clozapine
  - 0093-3086-84- 48 TABLET, ORALLY DISINTEGRATING in 1 CARTON (0093-3086-84)

0093- Teva Pharmaceuticals USA Inc
- 0093-3087- Clozapine
  - 0093-3087-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (0093-3087-01)

0093- Teva Pharmaceuticals USA Inc
- 0093-3087- Clozapine
  - 0093-3087-19- 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-3087-19)

0093- Teva Pharmaceuticals USA Inc
- 0093-3087- Clozapine
  - 0093-3087-84- 48 TABLET, ORALLY DISINTEGRATING in 1 CARTON (0093-3087-84)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4359- Clozapine
  - 0093-4359-01- 100 TABLET in 1 BOTTLE (0093-4359-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4359- Clozapine
  - 0093-4359-05- 500 TABLET in 1 BOTTLE (0093-4359-05)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4359- Clozapine
  - 0093-4359-93- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0093-4359-93) > 1 TABLET in 1 BLISTER PACK (0093-4359-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4404- Clozapine
  - 0093-4404-01- 100 TABLET in 1 BOTTLE (0093-4404-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4404- Clozapine
  - 0093-4404-05- 500 TABLET in 1 BOTTLE (0093-4404-05)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4404- Clozapine
  - 0093-4404-93- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0093-4404-93) > 1 TABLET in 1 BLISTER PACK (0093-4404-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4405- Clozapine
  - 0093-4405-01- 100 TABLET in 1 BOTTLE (0093-4405-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4405- Clozapine
  - 0093-4405-05- 500 TABLET in 1 BOTTLE (0093-4405-05)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-4405- Clozapine
  - 0093-4405-93- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0093-4405-93) > 1 TABLET in 1 BLISTER PACK (0093-4405-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5416- Clozapine
  - 0093-5416-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (0093-5416-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5417- Clozapine
  - 0093-5417-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (0093-5417-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5417- Clozapine
  - 0093-5417-84- 48 BLISTER PACK in 1 CARTON (0093-5417-84) > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5417-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5419- Clozapine
  - 0093-5419-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (0093-5419-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-5419- Clozapine
  - 0093-5419-84- 48 BLISTER PACK in 1 CARTON (0093-5419-84) > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (0093-5419-19)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7772- Clozapine
  - 0093-7772-01- 100 TABLET in 1 BOTTLE (0093-7772-01)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7772- Clozapine
  - 0093-7772-05- 500 TABLET in 1 BOTTLE (0093-7772-05)

0093- Teva Pharmaceuticals USA, Inc.
- 0093-7772- Clozapine
  - 0093-7772-93- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (0093-7772-93) > 1 TABLET in 1 BLISTER PACK (0093-7772-19)

0378- Mylan Pharmaceuticals Inc.
- 0378-0825- Clozapine
  - 0378-0825-01- 100 TABLET in 1 BOTTLE, PLASTIC (0378-0825-01)

0378- Mylan Pharmaceuticals Inc.
- 0378-0860- Clozapine
  - 0378-0860-01- 100 TABLET in 1 BOTTLE, PLASTIC (0378-0860-01)

0378- Mylan Pharmaceuticals Inc.
- 0378-0860- Clozapine
  - 0378-0860-05- 500 TABLET in 1 BOTTLE, PLASTIC (0378-0860-05)

0378- Mylan Pharmaceuticals Inc.
- 0378-0972- Clozapine
  - 0378-0972-01- 100 TABLET in 1 BOTTLE, PLASTIC (0378-0972-01)

0378- Mylan Pharmaceuticals Inc.
- 0378-0973- Clozapine
  - 0378-0973-01- 100 TABLET in 1 BOTTLE, PLASTIC (0378-0973-01)

0378- Mylan Pharmaceuticals Inc.
- 0378-3813- Clozapine
  - 0378-3813-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-3813-01)

0378- Mylan Pharmaceuticals Inc.
- 0378-3815- Clozapine
  - 0378-3815-01- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-3815-01)

0781- Sandoz Inc.
- 0781-5989- Clozapine
  - 0781-5989-01- 100 TABLET in 1 BOTTLE (0781-5989-01)

0781- Sandoz Inc.
- 0781-5992- Clozapine
  - 0781-5992-01- 100 TABLET in 1 BOTTLE (0781-5992-01)

16729- Accord Healthcare Inc.
- 16729-141- Clozapine
  - 16729-141-01- 100 TABLET in 1 BOTTLE (16729-141-01)

16729- Accord Healthcare Inc.
- 16729-141- Clozapine
  - 16729-141-16- 500 TABLET in 1 BOTTLE (16729-141-16)

16729- Accord Healthcare Inc.
- 16729-142- Clozapine
  - 16729-142-01- 100 TABLET in 1 BOTTLE (16729-142-01)

16729- Accord Healthcare Inc.
- 16729-142- Clozapine
  - 16729-142-16- 500 TABLET in 1 BOTTLE (16729-142-16)

18860- Jazz Pharmaceuticals, Inc.
- 18860-101- FazaClo
  - 18860-101-10- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (18860-101-10)

18860- Jazz Pharmaceuticals, Inc.
- 18860-102- FazaClo
  - 18860-102-01- 8 BLISTER PACK in 1 CARTON (18860-102-01) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

18860- Jazz Pharmaceuticals, Inc.
- 18860-102- FazaClo
  - 18860-102-10- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (18860-102-10)

18860- Jazz Pharmaceuticals, Inc.
- 18860-104- FazaClo
  - 18860-104-01- 8 BLISTER PACK in 1 CARTON (18860-104-01) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

18860- Jazz Pharmaceuticals, Inc.
- 18860-104- FazaClo
  - 18860-104-10- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (18860-104-10)

18860- Jazz Pharmaceuticals, Inc.
- 18860-105- FazaClo
  - 18860-105-01- 8 BLISTER PACK in 1 CARTON (18860-105-01) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

18860- Jazz Pharmaceuticals, Inc.
- 18860-105- FazaClo
  - 18860-105-10- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (18860-105-10)

18860- Jazz Pharmaceuticals, Inc.
- 18860-106- FazaClo
  - 18860-106-01- 8 BLISTER PACK in 1 CARTON (18860-106-01) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

18860- Jazz Pharmaceuticals, Inc.
- 18860-106- FazaClo
  - 18860-106-10- 100 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (18860-106-10)

51079- Mylan Institutional Inc.
- 51079-288- Clozapine
  - 51079-288-04- 40 BLISTER PACK in 1 CARTON (51079-288-04) > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK (51079-288-01)

51079- Mylan Institutional Inc.
- 51079-749- Clozapine
  - 51079-749-20- 100 BLISTER PACK in 1 CARTON (51079-749-20) > 1 TABLET in 1 BLISTER PACK (51079-749-01)

51079- Mylan Institutional Inc.
- 51079-921- Clozapine
  - 51079-921-20- 100 BLISTER PACK in 1 CARTON (51079-921-20) > 1 TABLET in 1 BLISTER PACK (51079-921-01)

51079- Mylan Institutional Inc.
- 51079-922- Clozapine
  - 51079-922-20- 100 BLISTER PACK in 1 CARTON (51079-922-20) > 1 TABLET in 1 BLISTER PACK (51079-922-01)

51862- Mayne Pharma
- 51862-271- Clozapine
  - 51862-271-01- 100 TABLET in 1 BOTTLE (51862-271-01)

51862- Mayne Pharma
- 51862-271- Clozapine
  - 51862-271-05- 500 TABLET in 1 BOTTLE (51862-271-05)

51862- Mayne Pharma
- 51862-272- Clozapine
  - 51862-272-01- 100 TABLET in 1 BOTTLE (51862-272-01)

51862- Mayne Pharma
- 51862-272- Clozapine
  - 51862-272-05- 500 TABLET in 1 BOTTLE (51862-272-05)

51862- Mayne Pharma
- 51862-273- Clozapine
  - 51862-273-01- 100 TABLET in 1 BOTTLE (51862-273-01)

51862- Mayne Pharma
- 51862-273- Clozapine
  - 51862-273-05- 500 TABLET in 1 BOTTLE (51862-273-05)

51862- Mayne Pharma
- 51862-274- Clozapine
  - 51862-274-01- 100 TABLET in 1 BOTTLE (51862-274-01)

51862- Mayne Pharma
- 51862-274- Clozapine
  - 51862-274-05- 500 TABLET in 1 BOTTLE (51862-274-05)

52817- TruPharma, LLC
- 52817-601- VERSACLOZ
  - 52817-601-38- 1 BOTTLE in 1 BOX (52817-601-38) > 100 mL in 1 BOTTLE

55154- Cardinal Health
- 55154-8285- Clozapine
  - 55154-8285-0- 10 BLISTER PACK in 1 BAG (55154-8285-0) > 1 TABLET in 1 BLISTER PACK

57664- Sun Pharmaceutical Industries, Inc.
- 57664-211- CLOZAPINE
  - 57664-211-13- 500 TABLET in 1 BOTTLE (57664-211-13)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-211- CLOZAPINE
  - 57664-211-88- 100 TABLET in 1 BOTTLE (57664-211-88)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-241- CLOZAPINE
  - 57664-241-13- 500 TABLET in 1 BOTTLE (57664-241-13)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-241- CLOZAPINE
  - 57664-241-88- 100 TABLET in 1 BOTTLE (57664-241-88)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-345- CLOZAPINE
  - 57664-345-13- 500 TABLET in 1 BOTTLE (57664-345-13)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-345- CLOZAPINE
  - 57664-345-88- 100 TABLET in 1 BOTTLE (57664-345-88)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-347- CLOZAPINE
  - 57664-347-13- 500 TABLET in 1 BOTTLE (57664-347-13)

57664- Sun Pharmaceutical Industries, Inc.
- 57664-347- CLOZAPINE
  - 57664-347-88- 100 TABLET in 1 BOTTLE (57664-347-88)

60429- GSMS, Incorporated
- 60429-989- Clozapine
  - 60429-989-01- 100 TABLET in 1 BOTTLE (60429-989-01)

60429- GSMS, Incorporated
- 60429-990- Clozapine
  - 60429-990-01- 100 TABLET in 1 BOTTLE (60429-990-01)

60429- GSMS, Incorporated
- 60429-990- Clozapine
  - 60429-990-05- 500 TABLET in 1 BOTTLE (60429-990-05)

60687- American Health Packaging
- 60687-404- CLOZAPINE
  - 60687-404-01- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-404-01) > 1 TABLET in 1 BLISTER PACK (60687-404-11)

60687- American Health Packaging
- 60687-415- CLOZAPINE
  - 60687-415-01- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-415-01) > 1 TABLET in 1 BLISTER PACK (60687-415-11)

60687- American Health Packaging
- 60687-426- CLOZAPINE
  - 60687-426-01- 100 BLISTER PACK in 1 BOX, UNIT-DOSE (60687-426-01) > 1 TABLET in 1 BLISTER PACK (60687-426-11)

65862- Aurobindo Pharma Limited
- 65862-844- CLOZAPINE
  - 65862-844-01- 100 TABLET in 1 BOTTLE (65862-844-01)

65862- Aurobindo Pharma Limited
- 65862-844- CLOZAPINE
  - 65862-844-05- 500 TABLET in 1 BOTTLE (65862-844-05)

65862- Aurobindo Pharma Limited
- 65862-844- CLOZAPINE
  - 65862-844-78- 10 BLISTER PACK in 1 CARTON (65862-844-78) > 10 TABLET in 1 BLISTER PACK (65862-844-10)

65862- Aurobindo Pharma Limited
- 65862-845- CLOZAPINE
  - 65862-845-01- 100 TABLET in 1 BOTTLE (65862-845-01)

65862- Aurobindo Pharma Limited
- 65862-845- CLOZAPINE
  - 65862-845-05- 500 TABLET in 1 BOTTLE (65862-845-05)

65862- Aurobindo Pharma Limited
- 65862-845- CLOZAPINE
  - 65862-845-78- 10 BLISTER PACK in 1 CARTON (65862-845-78) > 10 TABLET in 1 BLISTER PACK (65862-845-10)

65862- Aurobindo Pharma Limited
- 65862-846- CLOZAPINE
  - 65862-846-01- 100 TABLET in 1 BOTTLE (65862-846-01)

65862- Aurobindo Pharma Limited
- 65862-846- CLOZAPINE
  - 65862-846-05- 500 TABLET in 1 BOTTLE (65862-846-05)

65862- Aurobindo Pharma Limited
- 65862-846- CLOZAPINE
  - 65862-846-78- 10 BLISTER PACK in 1 CARTON (65862-846-78) > 10 TABLET in 1 BLISTER PACK (65862-846-10)

65862- Aurobindo Pharma Limited
- 65862-847- CLOZAPINE
  - 65862-847-01- 100 TABLET in 1 BOTTLE (65862-847-01)

65862- Aurobindo Pharma Limited
- 65862-847- CLOZAPINE
  - 65862-847-05- 500 TABLET in 1 BOTTLE (65862-847-05)

65862- Aurobindo Pharma Limited
- 65862-847- CLOZAPINE
  - 65862-847-78- 10 BLISTER PACK in 1 CARTON (65862-847-78) > 10 TABLET in 1 BLISTER PACK (65862-847-10)

69809- HLS Therapeutics (USA), Inc.
- 69809-0126- Clozaril
  - 69809-0126-5- 100 TABLET in 1 BOTTLE (69809-0126-5)

69809- HLS Therapeutics (USA), Inc.
- 69809-0127- Clozaril
  - 69809-0127-5- 100 TABLET in 1 BOTTLE (69809-0127-5)

72721- Heartwood Pharma
- 72721-1725- Clozapine
  - 72721-1725-5- 100 TABLET in 1 BOTTLE (72721-1725-5)

72721- Heartwood Pharma
- 72721-1750- Clozapine
  - 72721-1750-5- 100 TABLET in 1 BOTTLE (72721-1750-5)

72721- Heartwood Pharma
- 72721-1760- Clozapine
  - 72721-1760-5- 100 TABLET in 1 BOTTLE (72721-1760-5)

72721- Heartwood Pharma
- 72721-1770- Clozapine
  - 72721-1770-5- 100 TABLET in 1 BOTTLE (72721-1770-5)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Code ⬆